Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. John P. Chalmers
Prof. Lars Ryden,
By John P Chalmers, (Sydney, Australia)View Discussant report by Lars Ryden, FESC
Open the PresentationWatch the Webcast
List of Authors: John Chalmers 1() on behalf of the ADVANCE-ON Collaborative Group (1) The George Institute for Global Health, Sydney, Australia
BackgroundThe Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, was a 2x2 factorial trial whose blood pressure lowering arm demonstrated that the combination of perindopril-indapamide reduced all-cause mortality by 14%, cardiovascular death by 18% and vascular events by 9% in patients with type 2 diabetes. We present here the results of post-trial follow-up, conducted to determine whether these benefits were sustained.MethodsSurvivors, previously randomly assigned to perindopril-indapamide or placebo were invited to post-trial follow-up. Primary outcomes were all-cause mortality and major macrovascular events (myocardial infarction, stroke and death from a cardiovascular cause). Effects on pre-specified endpoints were compared according to previous randomised treatment. (ClinicalTrials.Gov NCT 0094286)ResultsBaseline characteristics of 11140 patients originally randomised, and 8494 who contributed to post-trial follow-up for a median of 5.9 years, were similar. Differences in blood pressure between the two groups disappeared by the first post-randomisation visit. The reductions in all-cause death and cardiovascular death recorded during active treatment were sustained to the end of post-trial follow-up (hazard ratios [95% confidence intervals] 0.91[0.84-0.99], p=0.03 and 0.88[0.77-0.99], p=0.04) respectively, but were diminished. The reductions in major macrovascular events were not significant (0.92[0.85-1.00], p=0.06)ConclusionsThese results emphasise the importance of active blood pressure lowering in patients with type 2 diabetes in both the short term and the long term in order to maximise survival and cardiovascular protection.
By Lars Ryden, FESC (Stockholm, Sweden)See Presenter abstract
Open the presentationWatch the Webcast
Clinical Trial Update Hot Line: Interventions and drug therapy